McKesson Corporation (NYSE:MCK) Receives $970.93 Average PT from Analysts

Shares of McKesson Corporation (NYSE:MCK) have received a consensus rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $972.2667.

MCK has been the subject of several research analyst reports. Raymond James Financial set a $970.00 price objective on McKesson in a report on Thursday, March 5th. Bank of America cut their price objective on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a report on Monday, April 6th. Wall Street Zen lowered McKesson from a “buy” rating to a “hold” rating in a report on Saturday, April 11th. Leerink Partners reaffirmed an “outperform” rating and issued a $1,085.00 price objective on shares of McKesson in a report on Thursday, March 5th. Finally, Evercore reaffirmed an “outperform” rating on shares of McKesson in a report on Thursday, March 5th.

Insider Transactions at McKesson

In related news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of McKesson stock in a transaction on Friday, February 6th. The stock was sold at an average price of $955.00, for a total value of $313,240.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Maria Martinez sold 349 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the sale, the director directly owned 301 shares of the company’s stock, valued at $282,900.87. This represents a 53.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 3,592 shares of company stock worth $3,518,555. 0.08% of the stock is currently owned by insiders.

Institutional Trading of McKesson

Several hedge funds have recently bought and sold shares of the stock. J.W. Cole Advisors Inc. lifted its position in shares of McKesson by 35.3% in the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after acquiring an additional 1,329 shares in the last quarter. Cullen Investment Group LTD. lifted its position in shares of McKesson by 550.4% in the fourth quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company’s stock valued at $3,811,000 after acquiring an additional 3,952 shares in the last quarter. Private Wealth Partners LLC lifted its position in shares of McKesson by 5.6% in the third quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after acquiring an additional 1,682 shares in the last quarter. AlphaQuest LLC lifted its position in shares of McKesson by 91.2% in the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock valued at $1,365,000 after acquiring an additional 843 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of McKesson by 12.4% in the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after acquiring an additional 36,451 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson Price Performance

MCK stock opened at $828.94 on Thursday. McKesson has a 1-year low of $637.00 and a 1-year high of $999.00. The business has a fifty day moving average price of $907.82 and a 200-day moving average price of $856.80. The stock has a market capitalization of $101.54 billion, a P/E ratio of 23.84, a P/E/G ratio of 1.22 and a beta of 0.42.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. During the same quarter in the previous year, the company posted $8.03 earnings per share. McKesson’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, analysts anticipate that McKesson will post 39.02 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be issued a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s payout ratio is presently 9.43%.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Apollo agreed to buy a minority stake in McKesson’s medical‑surgical solutions business for $1.25 billion, which monetizes a portion of the business, provides cash proceeds and signals third‑party investor interest in the asset. Apollo to acquire minority stake in McKesson’s medical-surgical solutions business for $1.25bn
• Positive Sentiment: McKesson’s board declared a quarterly dividend of $0.82 per share (payable July 1; record/ex‑div June 1), confirming steady cash return policy—modest yield but supportive for income‑oriented holders. McKesson Corporation Declares Quarterly Dividend
• Positive Sentiment: Analysis pieces highlight multi‑year earnings and EPS growth that underpin McKesson’s long‑term thesis as a compounding business, helping longer‑term investor conviction. Is McKesson Stock Still A High-Conviction Compounder?
• Neutral Sentiment: UBS lowered its price target from $1,012 to $1,000 but retained a Buy rating — still implying sizable upside from current levels, though the trim may temper upside expectations. UBS price target update
• Neutral Sentiment: Market attention is focused on McKesson’s Q4 FY2026 earnings due May 7; analysts expect double‑digit profit growth, making the report a near‑term catalyst that could swing sentiment either way. McKesson Earnings Preview: What to Expect
• Negative Sentiment: Recent coverage noted a more meaningful intraday/short‑term price drop relative to the broader market, which may reflect profit‑taking after recent gains and sensitivity to analyst commentary and near‑term catalysts. McKesson sees a more significant dip than broader market

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.